NCT00418275

Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.

A Dose Finding, Pharmacokinetic and Safety Study of a Recombinant Human Plasminogen Activator (HTU-PA) in Patients With Acute Ischemic Stroke

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (planned)
• Sponsor: Global Biotech · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety profiles of HTU-PA in patients with acute ischemic stroke.

Detailed description

Cerebrovascular disease, the third leading cause of death after heart disease and cancer in developed countries, has an overall prevalence of 794 per 100,000. In the United States, it is estimated that more than 400,000 patients are discharged each year from hospitals after a stroke. The loss of these patients from the work force and the extended hospitalization they require during recovery make serious economic impact. In Taiwan, Cerebrovascular disease is the second cause of death.

Conditions

• Cerebrovascular Accident

Interventions

Type	Name	Description
GENETIC	Recombinant Human Plasminogen Activator (HTUPA)

Timeline

• Start date: 2001-04-01
• Completion: 2004-06-01
• First posted: 2007-01-04
• Last updated: 2007-01-04

Locations

1 site across 1 country: Taiwan